COVAX in humanitarian settings

COVAX has supplied nearly half of the vaccines administered by governments in humanitarian settings and, along with the UN’s Inter-Agency Standing Committee (IASC), set up the Humanitarian Buffer to address the hardest-to-fill gaps in fragile and conflict contexts.

© UNICEF/UN0136204/LeMoyne

Latest news and articles

26 January 2023

Mothers in Nigeria’s Wassa IDP camp spread the word: breastfeeding can save infant lives

Breastfeeding has both nutritional and immune benefits for babies. Perhaps particularly in emergency settings like this one, it can make all the difference.

22 December 2022

The peril of polio control in shadow of war

Satellite imagery and deft negotiation are critical tools for polio vaccination teams working across the world’s conflict zones, writes Adeline Tchouakak.

24 November 2022

Flood-displaced Nigerians rely on humanitarian intervention to stay healthy as outbreaks threaten

Nigeria's worst flooding in over a decade has left communities in limbo, with residents homeless and at risk of disease. But humanitarian groups are rising to the occasion, distributing life-saving aid from food to mosquito nets, and raising…

31 October 2022

Somalia: four lessons from past experience of dealing with famine

The looming Somalian famine might be the first in a string of back-to-back catastrophes, says an expert.

7 October 2022

After the floods comes disease: IDP camps in flood-hit Pakistan

The short-term devastation of Pakistan’s horrendous floods is now giving way to long-term impacts, as disease and ill-health begins to spread among the country’s displaced persons camps.

21 September 2022

Cameroon maps out strategy to reach zero-dose children with immunisation

For children in fragile and conflict-prone settings who have been out of reach of the government’s immunisation programmes, there is hope.

12 September 2022

Flood-hit Pakistan faces spread of infectious diseases

Around 33 million people affected by floods that engulfed a third of Pakistan. Millions need immediate assistance as floods damage health facilities. Pakistan faces outbreaks of several diseases like diarrhoea, dengue and COVID-19.

25 August 2022

Where routine immunisation is anything but routine: vaccinating Rohingya children in Bangladesh

Health workers are pulling out all the stops to protect Royingya children in Cox’s Bazar. 

19 August 2022

Testimonies on the heightened COVID-19 vaccination among refugees

Voices of refugees, host community, health workers and experts speak about COVID-19 vaccination.

19 July 2022

Reaching zero-dose children in Nigeria’s IDP camps

In Nigeria’s insurgency-ridden north-east region, volunteers are taking the message of immunisation to IDP camps.

COVAX doses

Taking stock of humanitarian access to pandemic vaccines

Discussion paper on key learnings from the COVAX humanitarian buffer experience.



Throughout the pandemic COVAX and humanitarian agencies – via the UN’s Inter-Agency Standing Committee (IASC) – set up the Humanitarian Buffer to address the most unpredictable and hardest-to-fill gaps in global COVID-19 vaccine access, supporting governments and non-governmental agencies to deliver to vulnerable groups regardless of COVAX participant status.

The COVAX Humanitarian Buffer also embarked on what was a global first: seeking to directly allocate Emergency Use Listed (EUL) vaccines to non-state actors and support delivery. Up until now, it remains the only mechanism to attempt this. This ambition recognized two key features of humanitarian delivery: (1) the centrality of non-state actors in vaccination in humanitarian settings; and (2) the need for delivery pathways across borders to reach marginalized populations. 


Unprecedented collaboration: Design, operationalisation and implementation of the Humanitarian Buffer have been an unprecedented multistakeholder and multi-sectoral effort, involving COVAX co-leads Gavi, WHO and UNICEF and, through the IASC, the UN Office for the Coordination of Humanitarian Affairs (OCHA), the International Committee of the Red Cross (ICRC), Médecins Sans Frontières (MSF), and civil society platforms like the International Council of Voluntary Agencies (ICVA).

Securing access to vaccines: Gavi secured access to COVID-19 vaccines on behalf of the COVAX Facility, which dedicating up to 5% of the volume available for the Facility to the Humanitarian Buffer so that humanitarian agencies and/or governments could reach marginalized communities.

Addressing systemic barriers: During the COVID-19 pandemic manufacturers required those procuring and delivering vaccines to take on indemnification related to novel vaccines. Recognizing that humanitarian agencies, who are often best placed to reach vulnerable groups, could not take on this burden, Gavi negotiated indemnity and liability waivers with six manufacturers within the COVAX portfolio securing access to seven COVID-19 pandemic vaccines (Covishield, Covovax, J&J, Clover, Sinopharm, Sinovac, Novavax).

Delivering to humanitarian settings: COVAX has delivered nearly 50%  of COVID-19 vaccines used by governments for immunization in humanitarian contexts. In addition, the Buffer has delivered nearly 2.5 million doses to support immunization of displaced persons and host communities in Iran and Uganda.

Humanitarian buffer transition

The nature of the challenge has shifted since the Buffer was first designed: COVID-19 vaccine supply is no longer constrained, global demand has slowed, countries and humanitarian contexts in particular are dealing with multiple competing priorities. With the main need now funding and supporting effective delivery of available doses to vulnerable groups, partners will work through existing programmes and platforms, leveraging available COVID-19 delivery funding, to integrate the delivery of COVID-19 vaccines with other critical services in humanitarian contexts.

  • Pillar 1: Closing the application window to support the shift away from top-down supply to effective delivery and integration into routine services, the Buffer will no longer accept applications after 31 December 2022.
  • Pillar 2: Supporting delivery and integration with routine services COVAX Partners will work to provide coordinated support and resources for delivering COVID-19 vaccines in humanitarian settings, integrated into existing channels within each organization, for implementation by government and CSOs. This effort will be complementary to global and local efforts to integrate COVID-19 vaccination with routine programs.
  • Pillar 3: Documenting and actioning lessons learned COVAX’s work in humanitarian settings and the Humanitarian Buffer have generated critical learnings on addressing systemic roadblocks during an unprecedented global crisis. Partners are committed to a deeper dive into challenges to ensure improvements are made in the face of increasingly inevitable future pandemics.

Challenges & learning agenda

A key takeaway from the Buffer is that access during a pandemic, in settings where governments play an active role and can access groups, is feasible despite political and other complexities. However, many global health unilateral and multilateral actors have long faced difficulties operating in humanitarian settings. These challenges were exacerbated working with non-governmental actors to import and deliver novel products in a pandemic environment, particularly outside state-based architecture, proved incredibly challenging due to a range of systemic, legal and regulatory factors.

To date, the COVAX Humanitarian Buffer has received nine applications, of which six were approved; of which three were withdrawn, one is on hold indefinitely, and two have been fulfilled.

Initial learnings and recommendations, such as contingency waivers for humanitarian import during a pandemic, are outlined in a Gavi Discussion Paper and in the COVAX: Key Learnings for Future Pandemic Preparedness and Response white paper published by COVAX partners. Partners will work together on further knowledge products and collaborate on a plan of action for future pandemics.

COVAX Humanitarian Buffer Application: CLOSED

As of 31 December 2022, The COVAX Humanitarian Buffer is no longer accepting new applications. COVAX partners are working through existing programmes and platforms, leveraging available COVID-19 delivery funding, to integrate the delivery of COVID-19 vaccines with other services in humanitarian contexts. ​ 

*Participants will be required to complete and submit the Humanitarian Buffer Standard Reporting Form to Gavi. This reporting form must be completed and submitted within three months after the completion of the programme activities, or within nine months after the doses were received by the Participant, whichever date is earlier.

Ethics Hotline for the Humanitarian Buffer

Explore COVAX

July 15, 2020

COVAX Facility

Co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, COVAX aims to accelerate the development and manufacture of COVID-19 vaccines while guaranteeing fair and equitable access for every country.

November 17, 2020


Ensuring access to COVID-19 vaccines for
low- and middle-income economies

Last updated: 3 Jan 2023

Subscribe to our newsletter